Patents Assigned to Trellis Bioscience, LLC
-
Patent number: 12152068Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: GrantFiled: January 5, 2022Date of Patent: November 26, 2024Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
-
Patent number: 11773143Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.Type: GrantFiled: October 12, 2018Date of Patent: October 3, 2023Assignees: Trellis Bioscience, LLC, The Regents of the University of CaliforniaInventors: Rebecca Dubois, Stas Fedechkin, Lawrence M. Kauvar
-
Publication number: 20220259294Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: ApplicationFiled: January 5, 2022Publication date: August 18, 2022Applicant: TRELLIS BIOSCIENCE, LLCInventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON, Lauren Opremcak BAKALETZ, Steven David GOODMAN
-
Patent number: 11248040Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: GrantFiled: January 17, 2020Date of Patent: February 15, 2022Assignee: TRELLIS BIOSCIENCE, LLCInventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
-
Patent number: 11246928Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that hind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.Type: GrantFiled: November 5, 2019Date of Patent: February 15, 2022Assignees: CONTRAFECT CORPORATION, TRELLIS BIOSCIENCE, LLCInventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
-
Publication number: 20210277116Abstract: Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.Type: ApplicationFiled: May 24, 2021Publication date: September 9, 2021Applicant: TRELLIS BIOSCIENCE, LLCInventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
-
Publication number: 20210268096Abstract: Improvements to vaccines against RSV include G protein CCD portions complexed with mAb that block interaction with CX3C-R and modified forms of mAb to prolong serum half-life, as well as inhalable vaccines.Type: ApplicationFiled: February 5, 2021Publication date: September 2, 2021Applicant: Trellis Bioscience, LLCInventors: Milton J. Friedman, Lawrence M. Kauvar
-
Patent number: 11046764Abstract: Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.Type: GrantFiled: January 3, 2018Date of Patent: June 29, 2021Assignee: Trellis Bioscience, LLCInventors: Angeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence M. Kauvar
-
Publication number: 20210054075Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.Type: ApplicationFiled: November 6, 2020Publication date: February 25, 2021Applicant: Trellis Bioscience, LLCInventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
-
Patent number: 10858431Abstract: Monoclonal antibodies derived from the native human repertoire that bind the extracellular portion of Killer IgG Receptor (KIR) and pharmaceutical and veterinary compositions thereof are useful in treating cancer in human and other subjects.Type: GrantFiled: June 9, 2017Date of Patent: December 8, 2020Assignee: Trellis Bioscience, LLCInventors: Angeles Estelles, Mikhail Gishizky, Stefan Ryser, Lawrence M. Kauvar
-
Publication number: 20200190170Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: ApplicationFiled: January 17, 2020Publication date: June 18, 2020Applicant: TRELLIS BIOSCIENCE, LLCInventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON, Lauren Opremcak BAKALETZ, Steven David GOODMAN
-
Patent number: 10676520Abstract: Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.Type: GrantFiled: June 17, 2011Date of Patent: June 9, 2020Assignee: TRELLIS BIOSCIENCE, LLCInventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista M. McCutcheon, Minha Park, Bo Chen, Ying-Ping Jiang
-
Patent number: 10654915Abstract: Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.Type: GrantFiled: December 5, 2012Date of Patent: May 19, 2020Assignee: TRELLIS BIOSCIENCE, LLCInventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Minha Park
-
Patent number: 10639370Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.Type: GrantFiled: February 4, 2015Date of Patent: May 5, 2020Assignees: CONTRAFECT CORPORATION, TRELLIS BIOSCIENCE, LLCInventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
-
Patent number: 10570193Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: GrantFiled: November 5, 2018Date of Patent: February 25, 2020Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
-
Publication number: 20190135876Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.Type: ApplicationFiled: October 12, 2018Publication date: May 9, 2019Applicants: Trellis Bioscience, LLC, The Regents of the University of CaliforniaInventors: Rebecca DUBOIS, Stas FEDECHKIN, Lawrence M. KAUVAR
-
Patent number: 10233234Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: GrantFiled: May 2, 2016Date of Patent: March 19, 2019Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
-
Publication number: 20190055304Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: ApplicationFiled: November 5, 2018Publication date: February 21, 2019Applicant: Trellis Bioscience, LLCInventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Reyna J. SIMON, Lauren Opremcak BAKALETZ, Steven David GOODMAN
-
Patent number: 10030069Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.Type: GrantFiled: March 20, 2017Date of Patent: July 24, 2018Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
-
Publication number: 20180186880Abstract: Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.Type: ApplicationFiled: January 3, 2018Publication date: July 5, 2018Applicant: Trellis Bioscience, LLCInventors: Angeles ESTELLES, Mikhail GISHIZKY, Stefan RYSER, Lawrence M. KAUVAR
